{"id":"insulin-aspart-sar341402","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Weight gain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"SAR341402 is a modified insulin aspart formulation designed to provide faster onset and potentially improved pharmacokinetic properties compared to standard insulin aspart. It works by activating insulin receptors on muscle and adipose tissue, promoting glucose uptake and storage while suppressing hepatic glucose production, thereby lowering blood glucose levels in patients with diabetes.","oneSentence":"Insulin aspart SAR341402 is a rapid-acting insulin analog that binds to the insulin receptor to facilitate glucose uptake and utilization in peripheral tissues.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:16:21.151Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 1 diabetes mellitus"},{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT03874715","phase":"PHASE3","title":"Comparison of SAR341402 to NovoLog in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine","status":"COMPLETED","sponsor":"Sanofi","startDate":"2019-03-11","conditions":"Type 1 Diabetes Mellitus","enrollment":210},{"nctId":"NCT03436498","phase":"PHASE1","title":"Safety Assessment of SAR341402 and NovoLog® Used in Continuous Subcutaneous Insulin Infusion for Type 1 Diabetes Mellitus Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2018-05-10","conditions":"Type 1 Diabetes Mellitus","enrollment":45},{"nctId":"NCT03202875","phase":"PHASE1","title":"A Study to Compare Pharmacokinetics (PK) and Pharmacodynamics (PD) of SAR341402 to Insulin Aspart in Subjects With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Sanofi","startDate":"2012-11-14","conditions":"Type 1 Diabetes","enrollment":30},{"nctId":"NCT03916601","phase":"PHASE1","title":"Comparison of Exposure and Activity of SAR341402 Mix 70/30 to NovoLog Mix 70/30, NovoMix 30 and SAR341402 Rapid-acting Solution in Patients With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Sanofi","startDate":"2017-12-13","conditions":"Type 1 Diabetes","enrollment":52},{"nctId":"NCT03211858","phase":"PHASE3","title":"Comparison of SAR341402 to NovoLog/NovoRapid in Adult Patients With Diabetes Mellitus Also Using Insulin Glargine","status":"COMPLETED","sponsor":"Sanofi","startDate":"2017-08-02","conditions":"Type 1 Diabetes Mellitus-Type 2 Diabetes Mellitus","enrollment":597}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Insulin aspart SAR341402","genericName":"Insulin aspart SAR341402","companyName":"Sanofi","companyId":"sanofi","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Insulin aspart SAR341402 is a rapid-acting insulin analog that binds to the insulin receptor to facilitate glucose uptake and utilization in peripheral tissues. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}